FGFR3 and skeletal dysplasia: Because the FGFR3-driven skeletal dysplasia models are performed using neonatal mice, an experiment was designed to understand the pharmacokinetics of TYRA-300 at a relevant efficacious dose in male and female mice, ranging from 1 to 12 weeks of age.